Results from two Phase I trials evaluating the safety, pharmacokinetics and efficacy of BI 3006337, a dual fibroblast growth factor 21/glucagon-like peptide-1 agonist, in healthy volunteers and people with overweight/obesity and hepatic steatosis

Conference Reports for NATAP

EASL - European Association
for the Study of the Liver
Barcelona, Spain
May 27-30, 2026


Results from two Phase I trials evaluating the safety, pharmacokinetics and efficacy of BI 3006337, a dual fibroblast growth factor 21/glucagon-like peptide-1 agonist, in healthy volunteers and people with overweight/obesity and hepatic steatosis

	EASL 2026 May 26-30 Barcelona